Compare Diamondback Energy Inc (FANG) vs Pfizer Inc (PFE) Price & Performance

Diamondback Energy (FANG) trades at $190.69, showing slight daily weakness but maintaining a bullish technical outlook with strong analyst support. The company demonstrates solid revenue growth reaching $14.93B in 2025, though net margins have compressed to 1.88%. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed, with Q2 2026 results pending. The stock benefits from overwhelming analyst consensus with 90% buy ratings and a $234.50 price target representing 23% upside potential.

FANG presents a compelling growth story with expanding operations and strong cash generation, though investors face margin compression risks amid volatile energy markets. The stock's elevated P/E ratio of 193.63 reflects growth expectations, while technical indicators suggest near-term support around $189. Institutional sentiment remains positive with upcoming Q2 earnings on August 3, 2026, serving as the next key catalyst.

Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.

Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.